Jereme M. Sylvain - Dec 15, 2021 Form 4 Insider Report for DEXCOM INC (DXCM)

Role: EVP, Chief Financial Officer
Signature: Jereme M. Sylvain
Stock symbol: DXCM
Transactions as of: Dec 15, 2021
Transactions value $: $3
Form type: 4
Date filed: 12/17/2021, 03:40 PM
Previous filing: Dec 6, 2021
Next filing: Mar 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DXCM	Common Stock	Award	$2.93	+2.93K	+23.8%	$0.00^*	15.2K	Dec 15, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock.
F2	Included in this number are 12,684 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 804 of which were granted on March 8, 2019 and shall vest through March 8, 2022.

Content

Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/2 shall vest 24 months from the Grant Date, 1/8 shall vest 27 months from the Grant Date, 1/8 shall vest 30 months from the grant date, 1/8 shall vest 33 months from the Grant Date, and the remaining balance shall vest 36 months from the Grant Date. Share units represent a contingent right to receive one share of DexCom Inc. Common Stock.

Included in this number are 12,684 unvested restricted stock units, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 5,301 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,654 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 804 of which were granted on March 8, 2019 and shall vest through March 8, 2022.